证券代码：600513 证券简称：联环药业 公告编号：2023-034 江苏联环药业股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 27 日 至 2023 年 9 月 27 日 股东大会召开日期：2023年9月27日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一) 股东大会类型和届次 2023 年第一次临时股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2023 年 9 月 27 日 14 点 00 分 召开地点：扬州生物健康产业园健康一路 9 号 联环药业会议室 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为 ...

证券代码：600513 证券简称：联环药业 公告编号: 2023-033 江苏联环药业股份有限公司 关于修订《公司章程》的公告 江苏联环药业股份有限公司（以下简称"公司"、"联环药业"）于 2023 年 9 月 11 日召开第八届董事会第九次临时会议审议通过了《关于终止实施 2019 年限制 性股票激励计划暨回购注销已授予但尚未解除限售的限制性股票的议案》、《关于修 订<公司章程>的议案》，因终止实施 2019 年限制性股票激励计划暨回购注销已授予 但尚未解除限售的限制性股票事项减少注册资本的情况，对《公司章程》中相关条 款进行修订，具体情况如下： | 原条款 | 修改后条款 | | --- | --- | | 第六条 公司注册资本为人民币贰亿捌仟柒佰 | 第六条 公司注册资本为人民币贰亿捌仟伍 | | 壹拾肆万伍仟陆佰柒拾肆元（RMB287,145,674）。 | 佰肆拾伍万陆仟贰佰柒拾元（RMB285,456,270）。 | | 第二十七条 公司股份总数为 287,145,674 | 第二十七条 公司股份总数为 285,456,270 | | 股，公司的股本结构为：普通股 287,145,674 股。 | ...

证券代码：600513 证券简称：联环药业 公告编号：2023—031 江苏联环药业股份有限公司 关于控股子公司拟申请在新三板挂牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于2023年9月11日召开公 司第八届董事会第九次临时会议审议通过了《关于控股子公司拟申请在新三板挂 牌的议案》，同意公司控股子公司成都亚中生物制药有限责任公司（以下简称"亚 中制药"）拟申请在全国中小企业股份转让系统（以下简称"新三板"）挂牌， 本事项尚需提交公司股东大会审议。具体事项如下： 一、亚中制药基本情况 （一）基本情况 公司名称：成都亚中生物制药有限责任公司 注册资本：5000万元人民币 （三）主要经营情况 亚中制药最近一年又一期的主要财务数据如下： 公司类型：有限责任公司（自然人投资或控股） 成立日期：2002年11月14日 法定代表人：涂斌 经营范围：原料药生产、销售；货物进出口；黄姜种植、销售；医药中间体 生产、销售【依法须经批准的项目，经相关部门批准后方可开展经营活动】。 （二）股 ...

一、 说明会类型 证券代码：600513 证券简称：联环药业 公告编号：2023-028 江苏联环药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 9 月 8 日(星期五) 至 9 月 14 日(星期四)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 lhgf@lhpharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 江苏联环药业股份有限公司（以下简称"公司"）已于 2023 年 8 月 26 日发 布《公司 2023 年半年度报告》，为便于广大投资者更全面深入地了解公司 2023 年上半年经营成果、财务状况，公司计划于 2023 年 9 月 15 日下午 14:00-15:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上半年的 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 954,649,770.62, representing a 6.46% increase compared to CNY 896,687,884.87 in the same period last year[18]. - The net profit attributable to shareholders of the listed company decreased by 6.29% to CNY 61,527,771.37 from CNY 65,657,158.08 year-on-year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 55,985,712.48, down 8.81% from CNY 61,391,547.11 in the previous year[18]. - Basic earnings per share for the first half of 2023 were CNY 0.21, down 8.70% from CNY 0.23 in the same period last year[19]. - The weighted average return on net assets decreased by 0.68 percentage points to 4.83% from 5.51% year-on-year[19]. - The total profit for the pharmaceutical manufacturing industry in the same period was CNY 1,794.5 billion, down 17.1% year-on-year[32]. - The company reported a total of 9,333 million RMB in expected related party transactions for 2023, with actual transactions amounting to 4,884.96 million RMB in the first half of 2023, representing approximately 52.3% of the expected amount[88]. Cash Flow and Assets - The net cash flow from operating activities was CNY 5,417,794.74, a significant improvement from a negative CNY 25,157,172.12 in the same period last year[18]. - Cash and cash equivalents decreased by 36.29% to CNY 210.64 million, accounting for 7.64% of total assets at the end of the reporting period[47]. - The total assets at the end of the reporting period were CNY 2,756,152,652.34, reflecting a 1.52% increase from CNY 2,714,939,149.33 at the end of the previous year[18]. - The company reported a total current asset of ¥1,342,528,782.09, slightly down from ¥1,368,558,285.45, a decrease of approximately 1.9%[100]. - The ending balance of cash and cash equivalents as of June 30, 2023, was ¥188,552,539.49, down from ¥211,056,513.37 at the end of June 2022[112]. Research and Development - Research and development expenses increased by 16.70% to CNY 33.52 million compared to the previous year[46]. - The company introduced 38 new talents, including 4 PhDs and 6 Masters, to enhance its innovation capabilities[40]. - The company completed Phase I clinical research for LH-1801 and is currently drafting the clinical summary report[40]. - The company has successfully developed and launched 2 national class I new drugs, 6 former class II new drugs, and 2 former class III new drugs[35]. Industry Position and Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on research, production, and sales, with a strong reputation domestically and internationally[22]. - The pharmaceutical manufacturing industry is a key strategic emerging industry in China, with continuous growth driven by factors such as aging population and increased healthcare investment[30]. - The company is positioned to benefit from the strategic opportunities presented by the "14th Five-Year Plan" for the pharmaceutical industry, promoting high-quality development[30]. - The company plans to continue its market expansion efforts, focusing on new product development and technological advancements in the upcoming quarters[122]. Environmental Management - The company emphasized its commitment to environmental protection and safety, being recognized as a key pollutant discharge unit by environmental authorities[62]. - The company has implemented a comprehensive risk management system to ensure sustainable and healthy development[62]. - The company has a focus on continuous improvement in safety and environmental management practices[62]. - The company has received multiple environmental impact assessment approvals for new production lines, including a new solid preparation production line and a new formulation filling production line[69]. Corporate Governance - The company committed to ensuring that its major shareholder, Lianhua Group, will not engage in competing businesses with Lianhua Pharmaceutical and its subsidiaries during the reporting period[84]. - Lianhua Group guarantees the independence of Lianhua Pharmaceutical's management team, ensuring that key executives do not hold positions in other companies controlled by Lianhua Group[85]. - The company will maintain an independent financial department and accounting system, ensuring that Lianhua Pharmaceutical can make independent financial decisions[86]. - The company has not reported any significant guarantees or violations during the reporting period[87]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 28,326[93]. - The largest shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., holds 108,718,516 shares, representing 37.86% of total shares[94]. - The company has no strategic investors or general corporations becoming top ten shareholders during the reporting period[96]. Financial Reporting and Compliance - The financial statements prepared by the company comply with the requirements of the accounting standards, accurately reflecting its financial position and operating results[140]. - The company has not disclosed any non-standard audit opinions or significant changes in the previous year's annual report[87]. - The company has implemented specific accounting policies and estimates based on its actual production and operational characteristics, particularly regarding revenue recognition[139].

证券代码：600513 证券简称：联环药业 公告编号：2023-027 江苏联环药业股份有限公司 会议就下列议案进行了认真审议，经与会董事以通讯方式投票表决，通过如 下决议： 1、审议通过《公司 2023 年半年度报告》全文及摘要 《公司 2023 年半年度报告》全文及摘要详见上海证券交易所网站 (www.sse.com.cn)。 （表决情况：赞成 9 票，反对 0 票，弃权 0 票。） 2、审议通过《关于公司继续接受控股股东财务资助的议案》 为支持公司经营发展，公司控股股东江苏联环药业集团有限公司于 2021 年 9 月向公司提供人民币 5000 万元财务资助，双方签订《借款合同》，借款期限为 2021 年 9 月 27 日起至 2022 年 9 月 26 日，借款利率不高于贷款市场报价利率， 公司无需对该项财务资助提供任何抵押或担保，实际支出的利息按资金进入公司 指定账户之日和用款天数计算，该事项于 2021 年 9 月 27 日经公司第八届董事会 第八届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 ...

证券代码：600513 证券简称：联环药业 公告编号：2023-023 江苏联环药业股份有限公司 关于召开 2022 年度业绩说明会的公告 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 18 日(星期四) 至 5 月 24 日(星期三)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lhgf@lhpharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 江苏联环药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 3 日发布 《公司 2022 年年度报告》，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 5 月 25 日下午 15:00-16:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 ...

2023 年第一季度报告 证券代码：600513 证券简称：联环药业 江苏联环药业股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 单位：元 币种：人民币 | 项目 | | 本报告期 | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减变动幅度(%) | | 营业收入 | | 451,680,716.64 | 11.70 | | 归属于上市公司股东的净利润 | | 31,119,932.73 | 2.34 | | 归属于上市公司股东的扣除非经常性损益的净利润 | | 29,192,471.64 | 11.48 | | 经营活动产生的现金流量净额 | | -16,026,393 ...

Financial Performance - The company's operating revenue for 2022 was approximately CNY 1.96 billion, representing an increase of 18.80% compared to CNY 1.65 billion in 2021[21]. - The net profit attributable to shareholders for 2022 was approximately CNY 141.37 million, an increase of 18.96% from CNY 118.84 million in 2021[21]. - The basic earnings per share for 2022 was CNY 0.49, up 19.51% from CNY 0.41 in 2021[20]. - The net cash flow from operating activities for 2022 was approximately CNY 127.59 million, a decrease of 7.77% compared to CNY 138.34 million in 2021[21]. - The total assets at the end of 2022 were approximately CNY 2.71 billion, reflecting a 15.29% increase from CNY 2.35 billion at the end of 2021[21]. - The net assets attributable to shareholders at the end of 2022 were approximately CNY 1.27 billion, an increase of 9.37% from CNY 1.16 billion at the end of 2021[21]. - The company’s operating costs increased by 7.8% year-on-year to 16,984.6 billion RMB in 2022[36]. - The company reported a net cash flow from operating activities of RMB 127.59 million, a decrease of 7.77% compared to the previous year[66]. - The company achieved a revenue of 1.955 billion RMB in 2022, representing an 18.80% year-on-year growth[51]. - The net profit attributable to the parent company was 141 million RMB, with an 18.96% increase compared to the previous year[51]. Research and Development - The company invested 107.18 million RMB in R&D, accounting for 5.48% of operating revenue, which is a 26.08% increase year-on-year[27]. - Research and development expenses rose by 39.06% to 92.44 million RMB, reflecting increased investment in R&D projects[52]. - The company has a strong R&D team, including academicians and high-quality talents, focusing on innovation and technology development[46]. - The company has successfully developed and launched 2 national class I new drugs, 6 former class II new drugs, and 2 former class III new drugs, with a total of 84 domestic patents, including 27 invention patents[46]. - The company completed Phase I clinical trials for the innovative diabetes drug LH-1801 and is currently conducting Phase I trials for the leukemia drug LH-1802[84]. - The company has made significant progress in the development of various innovative drugs, with multiple projects at different stages of clinical trials and evaluations[84]. - The company has established partnerships with several research institutions to enhance its R&D capabilities and innovation[82]. - The company achieved a significant increase in R&D investment for anti-tumor innovative drugs, with an increase of 505.51% compared to the previous year[93]. Market and Sales - The sales volume of Aipuleite tablets reached 86.01 million pieces, a year-on-year increase of 17.80%[29]. - Domestic sales revenue reached 1.901 billion RMB, up 20.23% year-on-year, while export sales dropped by 28.65%[56]. - The company’s sales network for formulation products covers the entire country, with sales offices established in key provinces and cities[39]. - The company’s main product, Aipulete Tablets, is recognized as a national class I new drug for treating benign prostatic hyperplasia[47]. - The company’s product, Dexamethasone Injection, was the first in the country to pass the consistency evaluation, and Azithromycin Tablets also passed this evaluation[83]. - The company won bids for key products, including Ebastine Tablets at 0.5657 CNY per tablet and Aminomethylbenzoic Acid Injection at 3.26 CNY per 10ml[77][78]. - The company is focused on expanding its market presence and developing new growth points through proactive marketing strategies[113]. Corporate Governance - The company has a structured board governance with independent directors and specialized committees to ensure compliance with legal and regulatory requirements[116]. - The company has established effective communication channels with shareholders, ensuring their rights and participation in major decisions[115]. - The company has a performance evaluation and incentive mechanism for senior management, aligning their compensation with company performance[117]. - The company ensures the independence of its operations and governance structure, with no interference from controlling shareholders[120]. - The company has committed to maintaining independent business operations, with adequate assets, personnel, and capabilities[120]. - The company has a clear plan for future governance and operational independence, ensuring compliance with legal and regulatory requirements[120]. Environmental Responsibility - The company has implemented various pollution control facilities, including organic waste gas treatment systems operational since 2013 and 2017[167]. - The company reported no exceedance of emission standards for major pollutants during the monitoring period[165]. - The company has established an environmental risk prevention system and conducted daily environmental hazard inspections, along with training and emergency drills[169]. - The company has committed to enhancing environmental awareness and compliance with regulations following the administrative penalties received[172]. - The company has engaged in various environmental monitoring and waste disposal practices, ensuring adherence to legal standards and promoting sustainable operations[173]. - The company has established a distributed photovoltaic project with a capacity of 1.526 MW to reduce carbon emissions, achieving a reduction of 651 tons of CO2 equivalent[179]. - The company has invested a total of 671,600 CNY in social responsibility projects, focusing on product quality, safety production, and environmental protection[180]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[128]. - New product launches are expected to contribute an additional 300 million yuan in revenue, with a focus on innovative drug formulations[127]. - The company is investing in market expansion, targeting a 25% increase in market share in the next two years[126]. - The company plans to accelerate talent acquisition and strengthen its R&D capabilities to drive innovation and enhance competitiveness in 2023[104]. - The company aims to enhance operational efficiency, targeting a reduction in production costs by 5% over the next year[126]. - The company is committed to enhancing safety and environmental management, ensuring compliance with regulations, and maintaining a green development approach[107]. Risk Management - The company does not foresee any significant risks that could materially affect its operations during the reporting period[7]. - The company faces risks related to industry policy changes, rising raw material and labor costs, and potential price reductions in drug procurement[112]. - The company has established a comprehensive quality management system to control production processes and mitigate risks associated with product quality issues[113].

Financial Performance - The company's revenue for Q3 2022 reached ¥515,595,632.46, representing a 25.50% increase compared to the same period last year[3] - Net profit attributable to shareholders was ¥33,630,926.08, reflecting a 6.51% year-over-year growth[3] - The net profit excluding non-recurring gains and losses was ¥33,002,691.37, up by 6.86% from the previous year[3] - Total operating revenue for the first three quarters of 2022 reached ¥1,412,283,517.33, an increase of 20.7% compared to ¥1,169,942,600.71 in the same period of 2021[12] - Net profit for the third quarter of 2022 was ¥120,423,496.23, representing a 19.7% increase from ¥100,536,929.89 in Q3 2021[13] - The total comprehensive income attributable to the parent company for the third quarter of 2022 was CNY 99,288,084.16, an increase from CNY 85,963,003.88 in the same period of 2021, representing a growth of approximately 15.5%[14] Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥2,561,269,571.57, an increase of 8.77% from the end of the previous year[3] - The total assets of the company as of Q3 2022 amounted to ¥2,561,269,571.57, an increase from ¥2,354,796,481.05 at the end of Q3 2021[11] - The company's total liabilities reached ¥1,193,313,483.56, up from ¥1,073,869,781.09 in the previous year[11] - The equity attributable to shareholders of the parent company increased to ¥1,222,419,476.70, compared to ¥1,158,113,000.72 in Q3 2021[11] Cash Flow - The company reported a net cash flow from operating activities of -¥28,877,037.46 for the year-to-date, indicating a significant decline of 143.72%[4] - The net cash flow from operating activities for the first three quarters of 2022 was negative CNY 28,877,037.46, compared to a positive CNY 66,054,135.50 in the same period of 2021, reflecting a significant decline[15] - Cash inflow from operating activities totaled CNY 1,579,652,825.75 for the first three quarters of 2022, compared to CNY 1,394,547,714.80 in 2021, marking an increase of approximately 13.3%[15] - The cash outflow from operating activities increased to CNY 1,608,529,863.21 in 2022 from CNY 1,328,493,579.30 in 2021, representing a rise of about 21.1%[15] - The net cash flow from investing activities for the third quarter of 2022 was negative CNY 162,644,694.93, an improvement from negative CNY 184,590,008.16 in the same period of 2021[16] - The cash inflow from financing activities for the first three quarters of 2022 was CNY 567,510,000.00, compared to CNY 409,000,000.00 in 2021, indicating an increase of approximately 38.8%[16] - The company’s cash flow from financing activities included CNY 554,500,000.00 in borrowings received, which was an increase from CNY 359,000,000.00 in the previous year[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,676[5] - The largest shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., holds 37.86% of the shares[6] Research and Development - Research and development expenses increased to ¥58,937,451.98 in Q3 2022, up 50.5% from ¥39,119,611.11 in Q3 2021[13] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[12] Earnings Per Share - Basic earnings per share for the quarter were ¥0.12, a 9.09% increase year-over-year[3] - The basic earnings per share for the third quarter of 2022 was CNY 0.35, up from CNY 0.30 in the previous year, indicating a growth of about 16.7%[14] Operating Costs and Profitability - Total operating costs for the first three quarters of 2022 were ¥1,272,183,006.75, up 20.8% from ¥1,053,144,292.42 in the previous year[12] - The company's gross profit margin improved to approximately 10.0% in the first three quarters of 2022, compared to 9.9% in the same period last year[12] - The company recorded government subsidies amounting to ¥1,253,560.08 during the reporting period[4]